Therapeutic implications of orally delivered immunomodulatory oligonucleotides

Molecular Therapy

Volumn 23, Issue 2, 2015, Pages 222-223

  Klinman, Dennis M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 6; TOLL LIKE RECEPTOR 9; NANOCAPSULE; OLIGODEOXYRIBONUCLEOTIDE; OLIGONUCLEOTIDE; STAT1 PROTEIN; STAT4 PROTEIN; STAT6 PROTEIN;

ALLERGY; ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; AUTOIMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DNA BINDING MOTIF; DNA SEQUENCE; DOWN REGULATION; DRUG ADMINISTRATION ROUTE; DRUG UPTAKE; HUMAN; IMMUNOMODULATION; INFECTION; INTERMETHOD COMPARISON; LUPUS VULGARIS; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; NOTE; OLIGONUCLEOTIDE THERAPY; PEYER PATCH; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SILICOSIS; SURVIVAL RATE; TH1 CELL; TH2 CELL; TOXIC SHOCK SYNDROME; ANIMAL; DRUG DELIVERY SYSTEM; IMMUNOLOGY; MALE; DAILY LIFE ACTIVITY; DRUG EFFICACY; ENCAPSULATION; IMMUNOREACTIVITY; IMMUNOSTIMULATION; INTERNALIZATION; LYMPHOCYTE PROLIFERATION; OUTCOME ASSESSMENT; PROTEIN PHOSPHORYLATION;

ANIMALS; DERMATITIS, ATOPIC; DRUG DELIVERY SYSTEMS; MALE; NANOCAPSULES; OLIGODEOXYRIBONUCLEOTIDES;

EID: 84922118367     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.251     Document Type: Note

References (14)

1. Krieg AM. (2006). Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5: 471-484
2. Klinman DM, Tross D, Klaschik S, Shirota H and Sato T. (2009). Therapeutic applications and mechanisms underlying the activity of immunosuppressive oligonucleotides. Ann NY Acad Sci 1175: 80-88
3. Wang Y, Yamamoto Y, Shigemori S, Watanabe T, Oshiro K, Wang X., et al. (2015). Inhibitory/suppressive oligodeoxynucleotide nanocapsules as simple oral delivery devices for preventing atopic dermatitis in mice. Mol Ther 23: 297-309
4. Klinman DM. (2004). Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 4: 249-258
5. Ito Y, Shigemori S, Sato T, Shimazu T, Hatano K, Otani H., et al. (2013). Class I/II hybrid inhibitory oligodeoxynucleotide exerts Th1 and Th2 double immunosuppression. FEBS Open Bio 3: 41-45
6. Scheiermann J and Klinman DM. (2014). Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. Vaccine 32: 6377-6389
7. Lenert P, Stunz L, Yi, AK, Krieg AM and Ashman RF. (2001). CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation. Antisense Nucleic Acid Drug Dev 11: 247-256
8. Shirota H, Gursel I, Gursel M and Klinman DM. (2005). Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock. J Immunol 174: 4579-4583
9. Kamdar K, Nguyen V and DePaolo RW. (2013). Toll-like receptor signaling and regulation of intestinal immunity. Virulence 4: 207-212
10. Murchie AI. (1994). Tetraplex folding of telomere sequences and the inclusion of adenine bases. EMBO J 13: 993-1001
11. Gursel I, Gursel M, Yamada H, Ishii KJ, Takeshita F and Klinman DM. (2003). Repetitive elements in mammalian telomeres suppress bacterial DNAinduced immune activation. J Immunol 171: 1393-1400
12. McDermott AJ and Huffnagle GB. (2014). The microbiome and regulation of mucosal immunity. Immunology 142: 24-31
13. McCluskie MJ and Davis HL. (2000). Oral intrarectal and intranasal immunizations using CpG and non- CpG oligodeoxynucleotides as adjuvants. Vaccine 19: 413-422
14. Shirota Y, Shirota H and Klinman DM. (2012). Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol 188: 1592-1599